Publication: The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity
Authors
Fresno, Carlos del ; García Arriaza, Juan ; Martínez Cano, Sarai ; Heras Murillo, Ignacio ; Jarit Cabanillas, Aitor ; Amores Iniesta, Joaquín ; Brandy, Paola ; Dunphy, Gillian ; Suay Corredera, Carmen ; Pricolo, María Rosaria ; Vicente, Natalia ; López Perrote, Andrés ; Cabezudo, Sofía ; González Corpas, Ana ; Llorca, Oscar ; Alegre Cebollada, Jorge ; Garaigorfa, Urtzi ; Gastaminza, Pablo ; Esteban, Mariano ; Sancho, David
item.page.secondaryauthor
item.page.director
Publisher
Frontiers Media
publication.page.editor
publication.page.department
DOI
https://doi.org/10.3389/fimmu.2021.748103
item.page.type
info:eu-repo/semantics/article
Description
© The Author(s) 2021. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/
This document is the Published version of a Published Work that appeared in final form in Frontiers in Immunology. To access the final edited and published work see https://doi.org/10.3389/fimmu.2021.748103
Abstract
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.
publication.page.subject
Citation
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by/4.0/